August 2025 update

In short

FGF-1 research in Parkinson's continued, with higher dosing under study. The update also covered plans in other conditions.

Most of the August 2025 update covered other research areas and company business. The part about the brain research was short.

Dan Montano, the chief executive, wrote that Zhittya was continuing its work in Parkinson's disease, stroke, dementia and other brain conditions. He said the team had seen improvements but had still not worked out the best dosing.

The team was continuing to raise the dose in steps, checking each new level before moving participants to it. Mr. Montano wrote that he was the first person to try the new levels. Some participants had by then been dosed for three years. A person dosed in September 2025 would receive about 40 times more FGF-1 than the first participants received three years earlier.

Once the team had identified the best dosing schedule, the plan was to take it into studies under the FDA. The same approach was being followed for stroke recovery, dementia and other brain conditions.

Mr. Montano pointed to the functional MRI result from the first participant scanned, which showed increased blood flow to the substantia nigra six months after the first dose. He believed the team was on the right path while still having much to learn. In his closing section he added that improvement in participants with Parkinson's had not come as fast as he had hoped.

The update noted that the brain imaging studies at Washington University in St. Louis were continuing. It did not include participant comments this month.

This summary covers the Parkinson's research in the August 2025 update. The complete update, including the other topics it covered, is below.